We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
Read MoreHide Full Article
Integer Holdings Corporation (ITGR - Free Report) is well-poised for growth on portfolio management, and strong presence in the broader MedTech space.
Shares of Integer Holdings have gained 17.1% in a year’s time, compared with the industry’s growth of 13.5%. Meanwhile, the S&P 500 Index rose 41.9% in the same time frame.
The company, with a market capitalization of $3.08 billion, manufactures and develops medical devices and components primarily for original equipment manufacturers (OEMs), which depend on it to design, develop and produce intellectual property protected medical device technologies. It has a trailing four-quarter earnings surprise of 15.9%, on average.
Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #2 (Buy).
What’s Favoring the Stock?
Integer Holdings has initiated a new approach to drive sales and profitable growth, following a comprehensive strategic review of the business. Its new strategy has two overarching themes that are focused on portfolio management and operational excellence. This will help the company to realize its vision of enhancing patient lives.
Per the first-quarter 2021 earnings call, the company has maintained strategic investments amid the pandemic. Notably, management is optimistic that its customers and patients are ultimately benefiting from the same.
The company plans to invest more in the areas of Cardio & Vascular, Neuromodulation, and Electrochem to accelerate sales and market penetration. Integer Holdings has also been enhancing profitability in areas of Advanced Surgical, Orthopedics, and Power Solutions through focused sales growth and cost structure initiatives.
Further, it continues to benefit from strong presence in the broader MedTech space. This, in turn, will drive overall performance.
Estimates Trend
For 2021, the Zacks Consensus Estimate for revenues is pegged at $1.20 billion, indicating an improvement of 11.3% from the year-ago period. The same for earnings stands at $3.85 per share, suggesting growth of 38.9% from the previous year.
HCA Healthcare’s long-term earnings growth rate is expected at 12.3%.
DaVita’s long-term earnings growth rate is estimated at 14.4%.
Amedisys’ long-term earnings growth rate is estimated at 12%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
Integer Holdings Corporation (ITGR - Free Report) is well-poised for growth on portfolio management, and strong presence in the broader MedTech space.
Shares of Integer Holdings have gained 17.1% in a year’s time, compared with the industry’s growth of 13.5%. Meanwhile, the S&P 500 Index rose 41.9% in the same time frame.
The company, with a market capitalization of $3.08 billion, manufactures and develops medical devices and components primarily for original equipment manufacturers (OEMs), which depend on it to design, develop and produce intellectual property protected medical device technologies. It has a trailing four-quarter earnings surprise of 15.9%, on average.
Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #2 (Buy).
What’s Favoring the Stock?
Integer Holdings has initiated a new approach to drive sales and profitable growth, following a comprehensive strategic review of the business. Its new strategy has two overarching themes that are focused on portfolio management and operational excellence. This will help the company to realize its vision of enhancing patient lives.
Per the first-quarter 2021 earnings call, the company has maintained strategic investments amid the pandemic. Notably, management is optimistic that its customers and patients are ultimately benefiting from the same.
The company plans to invest more in the areas of Cardio & Vascular, Neuromodulation, and Electrochem to accelerate sales and market penetration. Integer Holdings has also been enhancing profitability in areas of Advanced Surgical, Orthopedics, and Power Solutions through focused sales growth and cost structure initiatives.
Further, it continues to benefit from strong presence in the broader MedTech space. This, in turn, will drive overall performance.
Estimates Trend
For 2021, the Zacks Consensus Estimate for revenues is pegged at $1.20 billion, indicating an improvement of 11.3% from the year-ago period. The same for earnings stands at $3.85 per share, suggesting growth of 38.9% from the previous year.
Other Stocks to Consider
Some other top-ranked stocks from the broader medical space are HCA Healthcare, Inc. (HCA - Free Report) , DaVita Inc. (DVA - Free Report) and Amedisys, Inc. (AMED - Free Report) , each currently carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
HCA Healthcare’s long-term earnings growth rate is expected at 12.3%.
DaVita’s long-term earnings growth rate is estimated at 14.4%.
Amedisys’ long-term earnings growth rate is estimated at 12%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>